OBR Daily Commentary

forumImage

This Tiny Biotech Spun A Quick $2 Billion From $12 Million

(MarketWatch) Oct 18, 2018 - Endocyte called its 2017 licensing deal ‘transformational’ — and it was right.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: October 19, 2018)

quotesThis deal is in part a result of the recognition that metastatic castration resistant prostate cancer (CRPC) is about to have fewer treatment options not more. With abiraterone, enzalutamide, and to a lesser extend docetaxel moving to earlier disease states, we are looking ahead to a new reality where chemotherapy will again play a major role in CRPC and options will be more limited. Hence, the PSMA targeted drug, if successful, will be a much needed addition. Naturally, success is far from guaranteed, but the need for more agents in CRPC is clear.quotes

Add Comment 1 Comment
forumImage

High-Dose Radiation Therapy Substantially Improves Survival In Patients Once Thought To Be Incurable

(ASTRO 2018) Oct 17, 2018 - In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live and doubles how long they live without cancer. The findings will be presented in a news briefing and the plenary session at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO) next week.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: October 18, 2018)

quotesThis is an exciting phase II result that suggests that carefully selected treatment of metastatic sites with radiation may substantially improve outcomes. With improving imaging, this approach may prove to be a significant advance. But it is critical that adequately sized phase III studies confirm this early and preliminary result.quotes

Add Comment 1 Comment
forumImage

Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer

(NASDAQ) Oct 5, 2018 - Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced data from its OSPREY 2301 Study of PyLTM (18F-DCFPyL).

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: October 08, 2018)

quotesThe results of OSPREY 2301 will need to be confirmed, but look quite promising and address one of the important needs in the field of prostate cancer. Improved imaging is essential to improve treatment decisions in early stage prostate cancer, and this approach may finally move us forward in this difficult area where little has changed in decades.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...